M
Min-Han Tan
Researcher at Agency for Science, Technology and Research
Publications - 186
Citations - 10277
Min-Han Tan is an academic researcher from Agency for Science, Technology and Research. The author has contributed to research in topics: Cancer & Renal cell carcinoma. The author has an hindex of 40, co-authored 173 publications receiving 8967 citations. Previous affiliations of Min-Han Tan include Singapore General Hospital & National Center for Charitable Statistics.
Papers
More filters
Journal ArticleDOI
8q24 and 17q Prostate cancer susceptibility loci in a multiethnic Asian cohort
Jason Yongsheng Chan,Huihua Li,Onkar Singh,Anupama Mahajan,Saminathan Ramasamy,Koilan Subramaniyan,Ravindran Kanesvaran,Hong Gee Sim,Tsung Wen Chong,Yik Ying Teo,Sin Eng Chia,Min-Han Tan,Balram Chowbay +12 more
TL;DR: This exploratory analysis suggests that the 5 genetic variants previously described may contribute to prostate cancer risk in Singaporean men.
Journal ArticleDOI
Predictive Factors for BRCA1 and BRCA2 Genetic Testing in an Asian Clinic-Based Population
Edward Sern Yuen Wong,Sandhya Shekar,Claire Hian Tzer Chan,Lewis Z. Hong,Suk-Yean Poon,Toomas Silla,Clarabelle Bitong Lin,Vikrant Kumar,Sonia Davila,Mathijs Voorhoeve,Aye Aye Thike,Yoon Sim Yap,Puay Hoon Tan,Min-Han Tan,Peter Ang,Ann S. G. Lee +15 more
TL;DR: Evidence is provided that TNBC or ER-negative patients may benefit from BRCA genetic testing, particularly younger patients (<40 years) or those with a strong FH of HBOC, in Asian patients.
Journal ArticleDOI
Metformin Use in Relation With Survival Outcomes of Patients With Renal Cell Carcinoma.
Jaryl Jun Sheng Cheng,Huihua Li,Hui Shan Tan,Puay Hoon Tan,Lay Guat Ng,Quan Sing Ng,Chee Keong Toh,Ravindran Kanesvaran,Min-Han Tan +8 more
TL;DR: Metformin use is correlated with improved survival in patients with localized RCC, but not in metastatic RCC; future studies should focus on its potential mechanisms and clinical utility.
Journal Article
Fumarate Hydratase-deficient Cell Line NCCFH1 as a New In Vitro Model of Hereditary Papillary Renal Cell Carcinoma Type 2.
Victoria Perrier-Trudova,Bernice W ong Huimin,Sarinya Kongpetch,Dachuan Huang,Pauline Ong,Audrey Le Formal,Song L ing Poon,Ee Y an Siew,Swe Swe Myint,Sophie Gad,Betty Gardie,Sophie Couvé,Yu M iin Foong,Yukti Choudhury,Jonathan Poh,Choon K iat Ong,Chee K eong Toh,Aikseng Ooi,Stéphane Richard,Min-Han Tan,Bin T ean Teh +20 more
TL;DR: It is demonstrated that the NCCFH1 cell line is a very interesting preclinical model for studying the metabolic features and testing new therapies for hereditary PRCC2, while bortezomib may be a potential efficient therapeutic option.
Journal ArticleDOI
Correction: The Singapore Liver Cancer Recurrence (SLICER) Score for Relapse Prediction in Patients with Surgically Resected Hepatocellular Carcinoma.
Soo Fan Ang,Elizabeth Shu-Hui Ng,Huihua Li,Yu-Han Ong,Su Pin Choo,Joanne Ngeow,Han Chong Toh,Kiat Hon Lim,Hao Yun Yap,Chee-Kiat Tan,London L.P.J. Ooi,Peng Chung Cheow,Alexander Y. F. Chung,Pierce K. H. Chow,Kian Fong Foo,Min-Han Tan +15 more
TL;DR: There is an error in the order of authors and the correct order is: Soo Fan Ang, Elizabeth Shu-Hui Ng, Huihua Li, Yu-Han Ong, Su Pin Choo, Joanne Ngeow, Han Chong Toh, Kian Fong Foo, Min-Han Tan.